Description
Anti-CTGF Antibody, Non-Fucosylated (BioBet-180ZP) is a human monoclonal IgG1, κ antibody against CTGF. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CTGF antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Connective Tissue Growth Factor
Background
CTGF (Connective Tissue Growth Factor) is a Protein Coding gene.
Diseases associated with CTGF include Systemic Scleroderma and Renal Fibrosis.
Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and PAK Pathway.
Gene Ontology (GO) annotations related to this gene include growth factor activity and integrin binding.
An important paralog of this gene is NOV.
Alternative Names
CTGF; connective tissue growth factor; CCN2; NOV2; HCS24; IGFBP8; IBP-8; IGFBP-8; CCN family member 2; IGF-binding protein 8; hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with CCN2 include Renal Fibrosis and Systemic Scleroderma.
Related Pathways
Its related pathways are NF-KappaB Family Pathway and amb2 Integrin signaling. An important paralog of this gene is CCN3.
Function
The main connective tissue mitotic attractant secreted by vascular endothelial cells. Promote the proliferation and differentiation of chondrocytes. Mediates heparin and divalent cation-dependent cell adhesion to many cell types, including fibroblasts, myofibroblasts, endothelial cells and epithelial cells. Enhance DNA synthesis induced by fibroblast growth factor.
Post-translational modifications
1.Glycosylation at Asn28, Thr193, and Asn225 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-180ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTGF. Pamrevlumab is a human monoclonal antibody that can be potentially used in the treatment of Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer. It inhibits connective tissue growth factor (CTGF).
Antibody Indication
Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer
